65 related articles for article (PubMed ID: 21641101)
1. Evidence to support the single-dose over the two-dose protocol for routine antenatal anti-D Rhesus prophylaxis: a prospective observational study.
MacKenzie IZ; Dutton S; Roseman F
Eur J Obstet Gynecol Reprod Biol; 2011 Sep; 158(1):42-6. PubMed ID: 21641101
[TBL] [Abstract][Full Text] [Related]
2. Clinical validation of routine antenatal anti-D prophylaxis questions the modelling predictions adopted by NICE for Rhesus D sensitisation rates: results of a longitudinal study.
Mackenzie IZ; Roseman F; Findlay J; Thompson K; McPherson K
Eur J Obstet Gynecol Reprod Biol; 2008 Jul; 139(1):38-42. PubMed ID: 18243487
[TBL] [Abstract][Full Text] [Related]
3. Compliance with routine antenatal rhesus D prophylaxis and the impact on sensitisations: observations over 14 years.
MacKenzie IZ; Findlay J; Thompson K; Roseman F
BJOG; 2006 Jul; 113(7):839-43. PubMed ID: 16827770
[TBL] [Abstract][Full Text] [Related]
4. The kinetics of routine antenatal prophylactic intramuscular injections of polyclonal anti-D immunoglobulin.
MacKenzie IZ; Roseman F; Findlay J; Thompson K; Jackson E; Scott J; Reed M
BJOG; 2006 Jan; 113(1):97-101. PubMed ID: 16398777
[TBL] [Abstract][Full Text] [Related]
5. Routine antenatal anti-D prophylaxis and patient compliance with the two-dose regimen.
Chaffe B; Ford J; Bills V
Transfus Med; 2007 Oct; 17(5):399-403. PubMed ID: 17903141
[TBL] [Abstract][Full Text] [Related]
6. Routine antenatal anti-D prophylaxis for RhD-negative women: a systematic review and economic evaluation.
Pilgrim H; Lloyd-Jones M; Rees A
Health Technol Assess; 2009 Feb; 13(10):iii, ix-xi, 1-103. PubMed ID: 19210896
[TBL] [Abstract][Full Text] [Related]
7. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy.
Koelewijn JM; de Haas M; Vrijkotte TG; Bonsel GJ; van der Schoot CE
Transfusion; 2008 Aug; 48(8):1721-9. PubMed ID: 18507749
[TBL] [Abstract][Full Text] [Related]
8. Routine antenatal Rhesus D immunoglobulin prophylaxis: the results of a prospective 10 year study.
MacKenzie IZ; Bowell P; Gregory H; Pratt G; Guest C; Entwistle CC
Br J Obstet Gynaecol; 1999 May; 106(5):492-7. PubMed ID: 10430201
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis.
Neovius M; Tiblad E; Westgren M; Kublickas M; Neovius K; Wikman A
BJOG; 2016 Jul; 123(8):1337-46. PubMed ID: 26663771
[TBL] [Abstract][Full Text] [Related]
10. Routine antenatal anti-D prophylaxis--is the protection adequate?
Davies J; Chant R; Simpson S; Powell R
Transfus Med; 2011 Dec; 21(6):421-6. PubMed ID: 21906191
[TBL] [Abstract][Full Text] [Related]
11. The economics of routine antenatal anti-D prophylaxis for pregnant women who are rhesus negative.
Chilcott J; Tappenden P; Lloyd Jones M; Wight J; Forman K; Wray J; Beverley C
BJOG; 2004 Sep; 111(9):903-7. PubMed ID: 15327602
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of 250 μg anti-D IgG in the third trimester of pregnancy: an observational study.
Tiblad E; Wikman A; Rane A; Jansson Y; Westgren M
Acta Obstet Gynecol Scand; 2012 May; 91(5):587-92. PubMed ID: 22352370
[TBL] [Abstract][Full Text] [Related]
13. Single dose v two-dose antenatal anti-D prophylaxis: a randomised controlled trial.
White SW; Cheng JC; Penova-Veselinovic B; Wang C; White M; Ingleby B; Arnold C; Pennell CE
Med J Aust; 2019 Sep; 211(6):261-265. PubMed ID: 31304600
[TBL] [Abstract][Full Text] [Related]
14. Anti-D in Rh(D)-negative pregnant women: are at-risk pregnancies and deliveries receiving appropriate prophylaxis?
Koby L; Grunbaum A; Benjamin A; Koby R; Abenhaim HA
J Obstet Gynaecol Can; 2012 May; 34(5):429-435. PubMed ID: 22555135
[TBL] [Abstract][Full Text] [Related]
15. Implementation of NICE recommendation for a policy of routine antenatal anti-D prophylaxis: a survey of UK maternity units.
Harkness M; Freer Y; Prescott RJ; Warner P
Transfus Med; 2008 Oct; 18(5):292-5. PubMed ID: 18937736
[TBL] [Abstract][Full Text] [Related]
16. An increased risk for non allo-immunization related intrauterine fetal death in RhD-negative patients.
Ben-David G; Sheiner E; Levy A; Erez O; Mazor M
J Matern Fetal Neonatal Med; 2008 Apr; 21(4):255-9. PubMed ID: 18330822
[TBL] [Abstract][Full Text] [Related]
17. [Prevention of fetomaternal rhesus-D allo-immunization. Practical aspects].
Cortey A; Brossard Y
J Gynecol Obstet Biol Reprod (Paris); 2006 Feb; 35(1 Suppl):1S123-1S130. PubMed ID: 16495838
[TBL] [Abstract][Full Text] [Related]
18. An audit of the investigation and use of anti-D immunoglobulin prophylaxis in Tayside.
Rennie I; Smith A; Smith R; Rawlinson PS; Clark P
Health Bull (Edinb); 2001 May; 59(3):150-4. PubMed ID: 12664753
[TBL] [Abstract][Full Text] [Related]
19. Single dose of anti-D immune globulin at 75 microg/kg is as effective as intravenous immune globulin at rapidly raising the platelet count in newly diagnosed immune thrombocytopenic purpura in children.
Tarantino MD; Young G; Bertolone SJ; Kalinyak KA; Shafer FE; Kulkarni R; Weber LC; Davis ML; Lynn H; Nugent DJ;
J Pediatr; 2006 Apr; 148(4):489-94. PubMed ID: 16647411
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of anti-D IgG in pregnant RhD-negative women.
Bichler J; Schöndorfer G; Pabst G; Andresen I
BJOG; 2003 Jan; 110(1):39-45. PubMed ID: 12504934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
